2024
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
Rüschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, Martini M, Cheng L, Tretiakova M, Mitchell C, Anders R, Robert M, Fahy D, Pyle M, Le Q, Yu L, Glass B, Baxi V, Babadjanova Z, Pratt J, Brutus S, Karasarides M, Hartmann A. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Virchows Archiv 2024, 484: 597-608. PMID: 38570364, DOI: 10.1007/s00428-024-03795-8.Peer-Reviewed Original ResearchConceptsPD-L1 expressionImmune checkpoint inhibitorsPD-L1Tumor cellsAssess programmed death ligand 1Assessment of PD-L1 expressionScoring of PD-L1 expressionInternational multi-institutional studyPD-L1 expression analysisFood and Drug Administration-approvedPD-L1 stainingDeath-ligand 1Drug Administration-approvedMulti-institutional studyCheckpoint inhibitorsUrothelial carcinomaPathological assessmentBiomarker expressionInterobserver variabilityLigand 1Cancer treatmentExpert pathologistsClinical settingMultinational studyPositive rate
2023
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaB7-H1 AntigenBiomarkers, TumorEsophagogastric JunctionHumansObserver VariationPathologistsRetrospective StudiesStomach NeoplasmsConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic review
2008
A Comparison of Hepatopathologists' and Community Pathologists' Review of Liver Biopsy Specimens From Patients With Hepatitis C
Robert M, Sofair AN, Thomas A, Bell B, Bialek S, Corless C, Van Ness G, Huie–White S, Stabach N, Zaman A. A Comparison of Hepatopathologists' and Community Pathologists' Review of Liver Biopsy Specimens From Patients With Hepatitis C. Clinical Gastroenterology And Hepatology 2008, 7: 335-338. PMID: 19138761, PMCID: PMC4603363, DOI: 10.1016/j.cgh.2008.11.029.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyHepatitis C, ChronicHumansLiverLiver CirrhosisObserver VariationPathologySeverity of Illness IndexConceptsHepatitis C patientsCommunity pathologistsBiopsy specimensC patientsLiver biopsyFibrosis stageInterobserver agreementChronic liver diseaseLiver biopsy specimensPopulation-based studyStage of fibrosisPopulation-based sampleGood overall interobserver agreementOverall interobserver agreementBiopsy specimen sizeDisease surveillance networksHepatitis CLiver histologyLiver diseaseHepatic fibrosisGeneral pathologistsStudy pathologistsHepatopathologistBiopsy samplesPatients